Laura Gramantieri

St. Orsola Malpighi University Hospital
Bologna, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications

Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma.

Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma.

Journal: Cells
Published: March 10, 2026

Corrigendum to < 'Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells'> <[Non-coding RNA Research vol. 13 (2025) 153-161]>.

Corrigendum to < 'Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells'> <[Non-coding RNA Research vol. 13 (2025) 153-161]>.

Journal: Non-coding RNA research
Published: February 02, 2026

Somatic pathogenic mitochondrial DNA mutations independently predict worse prognosis in hepatocellular carcinoma.

Somatic pathogenic mitochondrial DNA mutations independently predict worse prognosis in hepatocellular carcinoma.

Journal: Scientific reports
Published: January 22, 2026

TG221: An Experimental Model for Liver Cancer Prevention and Treatment Approaches.

TG221: An Experimental Model for Liver Cancer Prevention and Treatment Approaches.

Journal: Biotech (Basel (Switzerland))
Published: December 01, 2025

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.

Journal: Cell death discovery
Published: June 25, 2025

Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells.

Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells.

Journal: Non-coding RNA research
Published: March 10, 2025

MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma.

MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma.

Journal: International journal of molecular sciences
Published: March 08, 2025

Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC.

Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC.

Journal: Biomolecules
Published: October 10, 2024

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies.

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies.

Journal: Biomolecules
Published: October 01, 2024

Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab-bevacizumab resistance and worse survival in advanced hepatocarcinoma.

Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab-bevacizumab resistance and worse survival in advanced hepatocarcinoma.

Journal: ESMO open
Published: September 27, 2024

Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.

Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.

Journal: Scientific reports
Published: February 13, 2024

Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response.

Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response.

Journal: Cancers
Published: December 22, 2023
Showing 1-12 of 70

Last Updated: 09/26/2026